Opinion statement
Reversible cerebral vasoconstriction syndrome (RCVS) is a rare but increasingly recognized disorder with over 500 cases published in the literature. The condition is characterized by recurrent severe thunderclap headaches with or without other neurological symptoms and diffuse segmental narrowing of the cerebral arteries which is reversible within 3 months. RCVS may occur spontaneously but in over 50% of cases, it is associated with various other conditions, including vasoactive medications or illicit drugs and the post-partum state. One third to a half of cases develop hemorrhagic or ischemic brain lesions or a combination of both. Posterior reversible encephalopathy syndrome (PRES) often occurs in association with RCVS and the conditions are likely to share a common pathophysiology. The pathogenesis of RCVS remains uncertain but autonomic dysregulation, oxidative stress, and genetic predisposition are postulated. Significant differential diagnoses include subarachnoid hemorrhage (SAH) due to aneurysmal rupture, cervical artery dissection, and primary angiitis of the central nervous system (PACNS). Although there is no proven treatment, calcium channel antagonists including nimodipine and verapamil have been administered with reported reduction of headache intensity but without effect on the time course of cerebral vasoconstriction. Glucocorticoids have been reported as an independent predictor of worse outcome and should be avoided. The cornerstone of RCVS management remains largely supportive with bed rest and analgesics and removal of precipitating factors. Invasive neurointerventional techniques should be reserved for severe deteriorating cases. The condition is usually benign and self-limited and the majority of patients have a favorable outcome but around 5–10% are left with permanent neurological deficits and rare cases may die. This review details the importance of the early recognition of this increasingly described condition and current treatment recommendations.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as:•Of importance ••Of major importance
Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med. 2007;146(1):34–44.
•• Ducros A, Wolff V. The typical thunderclap headache of reversible cerebral vasoconstriction syndrome and its various triggers. Headache. 2016;56(4):657–73. doi:10.1111/head.12797. This paper is a recent comprehensive review article on the association of thunderclap headache and RCVS.
Dodick DW. Thunderclap headache. Headache. 2002;42(4):309–15.
Dodick DW, Brown Jr RD, Britton JW, Huston 3rd J. Nonaneurysmal thunderclap headache with diffuse, multifocal, segmental, and reversible vasospasm. Cephalalgia. 1999;19(2):118–23. doi:10.1046/j.1468-2982.1999.019002118.x.
Ducros A, Bousser MG. Reversible cerebral vasoconstriction syndrome. Pract Neurol. 2009;9(5):256–67. doi:10.1136/jnnp.2009.187856.
Chen SP, Fuh JL, Lirng JF, Chang FC, Wang SJ. Recurrent primary thunderclap headache and benign CNS angiopathy: spectra of the same disorder? Neurology. 2006;67(12):2164–9. doi:10.1212/01.wnl.0000249115.63436.6d.
Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11(10):906–17. doi:10.1016/S1474-4422(12)70135-7.
Headache Classification Committee of the International Headache S. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808. doi:10.1177/0333102413485658.
• Mawet J, Debette S, Bousser MG, Ducros A. The link between migraine, reversible cerebral vasoconstriction syndrome and cervical artery dissection. Headache. 2016;56(4):645–56. doi:10.1111/head.12798. This recent review highlights the recognized association of RCVS and cervical artery dissection and the possible association of migraine with both conditions.
Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain. 2007;130(Pt 12):3091–101. doi:10.1093/brain/awm256.
Ducros A, Fiedler U, Porcher R, Boukobza M, Stapf C, Bousser MG. Hemorrhagic manifestations of reversible cerebral vasoconstriction syndrome: frequency, features, and risk factors. Stroke. 2010;41(11):2505–11. doi:10.1161/STROKEAHA.109.572313.
Singhal AB, Hajj-Ali RA, Topcuoglu MA, Fok J, Bena J, Yang D, et al. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol. 2011;68(8):1005–12. doi:10.1001/archneurol.2011.68.
Calic Z, Cappelen-Smith C, Zagami AS. Reversible cerebral vasoconstriction syndrome. Intern Med J. 2015;45(6):599–608. doi:10.1111/imj.12669.
Chen SP, Fuh JL, Wang SJ, Chang FC, Lirng JF, Fang YC, et al. Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes. Ann Neurol. 2010;67(5):648–56. doi:10.1002/ana.21951.
Singhal AB. Reversible cerebral vasoconstriction syndromes: what the cardiologist should know. Curr Treat Options Cardiovasc Med. 2014;16(3):290. doi:10.1007/s11936-013-0290-1.
Call GK, Fleming MC, Sealfon S, Levine H, Kistler JP, Fisher CM. Reversible cerebral segmental vasoconstriction. Stroke. 1988;19(9):1159–70.
Bogousslavsky J, Despland PA, Regli F, Dubuis PY. Postpartum cerebral angiopathy: reversible vasoconstriction assessed by transcranial Doppler ultrasounds. Eur Neurol. 1989;29(2):102–5.
Fugate JE, Ameriso SF, Ortiz G, Schottlaender LV, Wijdicks EF, Flemming KD, et al. Variable presentations of postpartum angiopathy. Stroke. 2012;43(3):670–6. doi:10.1161/STROKEAHA.111.639575.
Ghia D, Cuganesan R, Cappelen-Smith C. Delayed angiographic changes in postpartum cerebral angiopathy. J Clin Neurosci. 2011;18(3):435–6. doi:10.1016/j.jocn.2010.07.103.
Jackson M, Lennox G, Jaspan T, Jefferson D. Migraine angiitis precipitated by sex headache and leading to watershed infarction. Cephalalgia. 1993;13(6):427–30. doi:10.1046/j.1468-2982.1993.1306427.x.
Martin K, Rogers T, Kavanaugh A. Central nervous system angiopathy associated with cocaine abuse. J Rheumatol. 1995;22(4):780–2.
Razavi M, Bendixen B, Maley JE, Shoaib M, Zargarian M, Razavi B, et al. CNS pseudovasculitis in a patient with pheochromocytoma. Neurology. 1999;52(5):1088–90.
Calabrese LH, Gragg LA, Furlan AJ. Benign angiopathy: a distinct subset of angiographically defined primary angiitis of the central nervous system. J Rheumatol. 1993;20(12):2046–50.
Hajj-Ali RA, Furlan A, Abou-Chebel A, Calabrese LH. Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term followup. Arthritis Rheum. 2002;47(6):662–9. doi:10.1002/art.10797.
Ducros A. Reversible cerebral vasoconstriction syndrome. Handb Clin Neurol. 2014;121:1725–41. doi:10.1016/B978-0-7020-4088-7.00111-5.
Chen SP, Fuh JL, Chang FC, Lirng JF, Shia BC, Wang SJ. Transcranial color doppler study for reversible cerebral vasoconstriction syndromes. Ann Neurol. 2008;63(6):751–7. doi:10.1002/ana.21384.
Katz BS, Fugate JE, Ameriso SF, Pujol-Lereis VA, Mandrekar J, Flemming KD, et al. Clinical worsening in reversible cerebral vasoconstriction syndrome. JAMA Neurol. 2014;71(1):68–73. doi:10.1001/jamaneurol.2013.4639.
•• Singhal AB, Topcuoglu MA, Fok JW, Kursun O, Nogueira RG, Frosch MP, et al. Reversible cerebral vasoconstriction syndromes and primary angiitis of the central nervous system: clinical, imaging, and angiographic comparison. Ann Neurol. 2016;79(6):882–94. doi:10.1002/ana.24652. This paper illustrates useful clinical and radiological differences between patients with RCVS and those with primary angiitis of the central nervous system in the largest cohort of patients studied with these conditions.
•• Topcuoglu MA, Singhal AB. Hemorrhagic reversible cerebral vasoconstriction syndrome: features and mechanisms. Stroke. 2016;47(7):1742–7. doi:10.1161/STROKEAHA.116.013136. This large retrospective study from a single center compares patients with hemorrhagic and non-hemorrhagic complications of RCVS and provides information on clinical features, time course, and outcome.
Calic Z, Choong H, Schlaphoff G, Cappelen-Smith C. Reversible cerebral vasoconstriction syndrome following indomethacin. Cephalalgia. 2014;34(14):1181–6. doi:10.1177/0333102414530526.
Chen SP, Fuh JL, Wang SJ. Reversible cerebral vasoconstriction syndrome: current and future perspectives. Expert Rev Neurother. 2011;11(9):1265–76. doi:10.1586/ern.11.112.
Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible cerebral vasoconstriction syndrome, part 1: epidemiology, pathogenesis, and clinical course. AJNR Am J Neuroradiol. 2015;36(8):1392–9. doi:10.3174/ajnr.A4214.
Yancy H, Lee-Iannotti JK, Schwedt TJ, Dodick DW. Reversible cerebral vasoconstriction syndrome. Headache. 2013;53(3):570–6. doi:10.1111/head.12040.
Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D. Reversible cerebral vasoconstriction syndrome, part 2: diagnostic work-up, imaging evaluation, and differential diagnosis. AJNR Am J Neuroradiol. 2015;36(9):1580–8. doi:10.3174/ajnr.A4215.
Chen SP, Fuh JL, Wang SJ. Reversible cerebral vasoconstriction syndrome: an under-recognized clinical emergency. Ther Adv Neurol Disord. 2010;3(3):161–71. doi:10.1177/1756285610361795.
Singhal AB, Ducros A. Reversible cerebral vasoconstriction syndrome stroke 5ed: Elsevier 2011. p. 765–71.
Hiraga A, Kuwabara S. Headache attributed to aeroplane travel and reversible cerebral vasoconstriction syndrome. Cephalalgia. 2016; doi:10.1177/0333102416678002.
Fisher CM. Cerebral ischemia—less familiar types. Clin Neurosurg. 1971;18:267–336.
Mawet J, Boukobza M, Franc J, Sarov M, Arnold M, Bousser MG, et al. Reversible cerebral vasoconstriction syndrome and cervical artery dissection in 20 patients. Neurology. 2013;81(9):821–4. doi:10.1212/WNL.0b013e3182a2cbe2.
Wolff V, Ducros A. Reversible cerebral vasoconstriction syndrome without typical thunderclap headache. Headache. 2016;56(4):674–87. doi:10.1111/head.12794.
Matharu MS, Schwedt TJ, Dodick DW. Thunderclap headache: an approach to a neurologic emergency. Curr Neurol Neurosci Rep. 2007;7(2):101–9.
Wilson D, Marshall CR, Solbach T, Watkins L, Werring DJ. Intraventricular hemorrhage in reversible cerebral vasoconstriction syndrome. J Neurol. 2014;261(11):2221–4. doi:10.1007/s00415-014-7499-0.
Lamy C, Oppenheim C, Mas JL. Posterior reversible encephalopathy syndrome. Handb Clin Neurol. 2014;121:1687–701. doi:10.1016/B978-0-7020-4088-7.00109-7.
Muehlschlegel S, Kursun O, Topcuoglu MA, Fok J, Singhal AB. Differentiating reversible cerebral vasoconstriction syndrome with subarachnoid hemorrhage from other causes of subarachnoid hemorrhage. JAMA Neurol. 2013;70(10):1254–60. doi:10.1001/jamaneurol.2013.3484.
Fukuma K, Ihara M, Tanaka T, Morita Y, Toyoda K, Nagatsuka K. Intracranial cerebral artery dissection of anterior circulation as a cause of convexity subarachnoid hemorrhage. Cerebrovasc Dis. 2015;40(1–2):45–51. doi:10.1159/000430945.
Yeh YC, Fuh JL, Chen SP, Wang SJ. Clinical features, imaging findings and outcomes of headache associated with sexual activity. Cephalalgia. 2010;30(11):1329–35. doi:10.1177/0333102410364675.
Chen SP, Fuh JL, Wang SJ, Tsai SJ, Hong CJ, Yang AC. Brain-derived neurotrophic factor gene Val66Met polymorphism modulates reversible cerebral vasoconstriction syndromes. PLoS One. 2011;6(3):e18024. doi:10.1371/journal.pone.0018024.
Chen SP, Chung YT, Liu TY, Wang YF, Fuh JL, Wang SJ. Oxidative stress and increased formation of vasoconstricting F2-isoprostanes in patients with reversible cerebral vasoconstriction syndrome. Free Radic Biol Med. 2013;61:243–8. doi:10.1016/j.freeradbiomed.2013.04.022.
Singhal AB, Kimberly WT, Schaefer PW, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 8-2009: a 36-year-old woman with headache, hypertension, and seizure 2 weeks post partum. N Engl J Med 2009;360(11):1126–1137. doi: 10.1056/NEJMcpc0809063.
Linn J, Fesl G, Ottomeyer C, Straube A, Dichgans M, Bruckmann H, et al. Intra-arterial application of nimodipine in reversible cerebral vasoconstriction syndrome: a diagnostic tool in select cases? Cephalalgia. 2011;31(10):1074–81. doi:10.1177/0333102410394673.
•• Singhal AB, Topcuoglu MA. Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome. Neurology. 2017;88(3):228–36. doi:10.1212/WNL.0000000000003510. This important recent study in the largest cohort of RCVS patients shows treatment with glucocorticoids is an independent predictor of poor outcome.
Meschia JF, Malkoff MD, Biller J. Reversible segmental cerebral arterial vasospasm and cerebral infarction: possible association with excessive use of sumatriptan and midrin. Arch Neurol. 1998;55(5):712–4.
Elstner M, Linn J, Muller-Schunk S, Straube A. Reversible cerebral vasoconstriction syndrome: a complicated clinical course treated with intra-arterial application of nimodipine. Cephalalgia. 2009;29(6):677–82. doi:10.1111/j.1468-2982.2008.01768.x.
Bouchard M, Verreault S, Gariepy JL, Dupre N. Intra-arterial milrinone for reversible cerebral vasoconstriction syndrome. Headache. 2009;49(1):142–5. doi:10.1111/j.1526-4610.2008.01211.x.
Song JK, Fisher S, Seifert TD, Cacayorin ED, Alexandrov AV, Malkoff MD, et al. Postpartum cerebral angiopathy: atypical features and treatment with intracranial balloon angioplasty. Neuroradiology. 2004;46(12):1022–6. doi:10.1007/s00234-003-1129-3.
Fugate JE, Wijdicks EF, Rabinstein AA. Reversible postpartum cerebral vasoconstriction syndrome-reply. Arch Neurol. 2012;69(6):792–3. doi:10.1001/archneurol.2012.214.
•• Chen SP, Fuh JL, Lirng JF, Wang YF, Wang SJ. Recurrence of reversible cerebral vasoconstriction syndrome: a long-term follow-up study. Neurology. 2015;84(15):1552–8. doi:10.1212/WNL.0000000000001473. This is the largest prospective study to investigate RCVS recurrence and long-term patient outcomes.
• John S, Singhal AB, Calabrese L, Uchino K, Hammad T, Tepper S, et al. Long-term outcomes after reversible cerebral vasoconstriction syndrome. Cephalalgia. 2016;36(4):387–94. doi:10.1177/0333102415591507. This recent study from two centers in the USA provides follow-up information in patients with RCVS to a median duration of 6.5 years.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Cecilia Cappelen-Smith, Zeljka Calic, and Dennis Cordato declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Cerebrovascular Disorders
Rights and permissions
About this article
Cite this article
Cappelen-Smith, C., Calic, Z. & Cordato, D. Reversible Cerebral Vasoconstriction Syndrome: Recognition and Treatment. Curr Treat Options Neurol 19, 21 (2017). https://doi.org/10.1007/s11940-017-0460-7
Published:
DOI: https://doi.org/10.1007/s11940-017-0460-7